Anixa Biosciences (NASDAQ:ANIX) Director Buys $27,300.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the transaction, the director directly owned 996,967 shares of the company’s stock, valued at $2,721,719.91. This represents a 1.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $2.60 on Thursday. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46. The company has a 50-day simple moving average of $3.31 and a two-hundred day simple moving average of $2.98. The company has a market capitalization of $90.38 million, a price-to-earnings ratio of -8.12 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). On average, sell-side analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Anixa Biosciences during the second quarter valued at about $559,000. GSA Capital Partners LLP bought a new position in Anixa Biosciences during the second quarter worth about $329,000. Bank of New York Mellon Corp purchased a new position in shares of Anixa Biosciences in the second quarter worth about $133,000. Corient Private Wealth LP purchased a new position in shares of Anixa Biosciences in the second quarter worth about $105,000. Finally, Kestra Advisory Services LLC increased its stake in shares of Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after purchasing an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Analyst Ratings Changes

ANIX has been the topic of a number of recent analyst reports. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings lowered Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.